

Product datasheet for **TL320342V**

Her2 (ERBB2) Human shRNA Lentiviral Particle (Locus ID 2064)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Her2 (ERBB2) Human shRNA Lentiviral Particle (Locus ID 2064)
Locus ID:	2064
Synonyms:	CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ERBB2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001005862 , NM_001289936 , NM_001289937 , NM_001289938 , NM_004448 , NR_110535 , NM_004448.1 , NM_004448.2 , NM_004448.3 , NM_001005862.1 , NM_001005862.2 , NM_001289938.1 , NM_001289937.1 , NM_001289936.1 , BC080193 , BC110392 , BC156755 , BC167147 , BM678576 , NM_001289936.2 , NM_001005862.3 , NM_001289938.2 , NM_001289937.2 , NM_004448.4
UniProt ID:	P04626
Summary:	This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).